Results 291 to 300 of about 713,346 (360)

LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice [PDF]

, 2018
Jeong, Lak Shin, Jeong, Se-Jin, Kim, Gyudong, Oh, Goo Taeg, Park, Jong-Gil, Yu, Jinha   +5 more
core   +1 more source

ONC206 as a low-potency dopamine D₂ receptor antagonist. [PDF]

Neurooncol Adv
Ågren R, Sahlholm K.
europepmc   +1 more source

Implication of the Dose of Mineralocorticoid Receptor Antagonist Following Transcatheter Edge-to-Edge Mitral Valve Repair. [PDF]

JACC Asia
Imamura T, Tanaka S, Fukuda N, Ueno H, Kinugawa K, Kubo S, Yamamoto M, Izumi Y, Saji M, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Naganuma T, Bota H, Ohno Y, Hachinohe D, Yamawaki M, Mizutani K, Otsuka T, Hayashida K, the, OCEAN-Mitral Investigators.   +27 more
europepmc   +1 more source

Role of AT1angiotensin receptor antagonist in pulmonary complications induced by renal ischemia-reperfusion injury in male and female rats. [PDF]

BMC Nephrol
Ahmadi S, Nahavandi S, Dehghani A, Sobhani SA, Abbasi T.   +4 more
europepmc   +1 more source

Evaluation of Four Semi-Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes. [PDF]

CPT Pharmacometrics Syst Pharmacol
Tan AYF, Schneck K, Garhyan P, Chan ECY, Tham LS.   +4 more
europepmc   +1 more source

2'-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist.

J Clin Endocrinol Metab
Guo Y, Liu B, Liang W, Cheng Y, Li H, Guan H, Xiao H, Li Y.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Vasopressin-Receptor Antagonists

Future Cardiology, 2010
Despite a crucial role in body fluid homeostasis, elevated vasopressin levels can also be pathological in conditions such as congestive heart failure, liver cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion. The result of elevated vasopressin is renal water retention and hyponatremia, a low serum sodium concentration ...
Hoorn, Ewout, Zietse, R.
openaire   +2 more sources

Endothelin Receptor Antagonists

Pharmacology & Therapeutics, 2006
Endothelin receptor antagonists (ERAs) have been developed to block the effects of endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful vasoconstrictor with mitogenic or co-mitogenic properties, which acts through the stimulation of 2 subtypes of receptors [endothelin receptor subtype A (ETA) and endothelin receptor subtype
J D, Elliott, E H, Ohlstein, C E, Peishoff, H M, Ellens, M A, Lago   +4 more
openaire   +4 more sources

AMPA Receptor Antagonists

Current Medicinal Chemistry, 2001
AMPA Receptor antagonists have received considerable attention in recent years. Within the class of excitatory amino acid receptor antagonists AMPA receptor antagonists have shown excellent neuroprotection in several models of cerebral ischemia and neuronal injury.
S S, Nikam, B E, Kornberg
openaire   +2 more sources